Carlsmed, Inc. (CARL) stock
CARLNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30118% above fair value
$17.74+0.39 (+2.25%)
Close on Nov 17, 2026Market cap $484.35MP/E –Yield –
Carlsmed r&d expenses
Research and development expenses are spending on new products and technology.
Carlsmed's R&D Expenses for the twelve months ending Jun 30, 2026 was $20.93M, up 45.7% year over year. For fiscal 2025 it was $17.02M, up 19.0% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.02M | +19.0% |
| FY2024 | Dec 31, 2024 | $14.30M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.04M | +45.2% |
| Q1 FY2026 | Mar 31, 2026 | $5.18M | +64.4% |
| Q4 FY2025 | Dec 31, 2025 | $5.26M | +74.6% |
| Q3 FY2025 | Sep 30, 2025 | $4.45M | +10.2% |
| Q2 FY2025 | Jun 30, 2025 | $4.16M | +4.1% |
| Q1 FY2025 | Mar 31, 2025 | $3.15M | – |
| Q4 FY2024 | Dec 31, 2024 | $3.02M | – |
| Q3 FY2024 | Sep 30, 2024 | $4.04M | – |
| Q2 FY2024 | Jun 30, 2024 | $4.00M | – |
See a number that looks wrong?